Bromide

Bromide

SCHEMBL812641

Br.PCCC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 14/20 0.52
KCNN4 O15554 1/20 0.42
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
KCNH2 Q12809 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.36
TSHR P16473 2/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5292521 0.97 KIF11 (0.54) KIF11KCNN4CYP11B1CYP11B2KCNH2
Iodide SCHEMBL5085031 0.95 KIF11 (0.52) KIF11KCNN4CYP11B1CYP11B2KCNH2
Hydrochloric Acid SCHEMBL5092615 0.95 KIF11 (0.52) KIF11KCNN4CYP11B1CYP11B2KCNH2
Bromide SCHEMBL1568274 0.86 KIF11 (0.59) KIF11CYP11B1CYP11B2KCNH2CYP3A4
Bromide SCHEMBL28967851 0.84 KIF11 (0.57) KIF11CYP11B1CYP11B2KCNH2CYP3A4
SCHEMBL1127900 0.83 KIF11 (0.61) KIF11CYP11B1CYP11B2KCNH2CYP3A4
Bromide SCHEMBL3785728 0.82 KIF11 (0.55) KIF11CYP11B1CYP11B2KCNH2CYP3A4
Bromide SCHEMBL5092309 0.82 KIF11 (0.55) KIF11CYP11B1CYP11B2KCNH2CYP3A4
Bromide SCHEMBL678763 0.82 KIF11 (0.55) KIF11CYP11B1CYP11B2KCNH2CYP3A4
Bromide SCHEMBL10797449 0.82 KIF11 (0.55) KIF11CYP11B1CYP11B2KCNH2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119978028-A Preparation method of high-temperature-resistant phosphorus salt antistatic agent 达创新材料科技(山东)有限公司 2025-05-13 CN claimed
CN-112358497-A Preparation method of polysulfide silane coupling agent with lighter color 南京曙光精细化工有限公司 2021-02-12 CN claimed
CN-107353858-B Packaging adhesive for infrared LED chip and preparation method and application thereof 广州惠利电子材料有限公司 2020-11-10 CN claimed
CN-111234185-A High-crystallinity bifunctional polyester resin for low-temperature curing extinction powder coating and synthesis method thereof 浙江光华科技股份有限公司 2020-06-05 CN claimed
CN-111205618-A Low-temperature impact-resistant high-transmittance flame-retardant polycarbonate composite material and preparation method thereof 宁波坚锋新材料有限公司 2020-05-29 CN claimed
US-9522915-B2 Method for preparing an important intermediate of linagliptin 2Y-CHEM, LTD. (CN) 2016-12-20 US claimed
US-20150274728-A1 METHOD FOR PREPARING AN IMPORTANT INTERMEDIATE OF LINAGLIPTIN 2Y-CHEM, LTD. (CN) 2015-10-01 US claimed
EP-0764676-B1 Method of preparing polycarbonate-polysiloxane block copolymers GEN ELECTRIC (US) 2004-04-28 EP claimed
EP-0010843-B1 METHOD OF MAKING 5,6-DIHYDRO-2-METHYL-N-PHENYL-1,4-OXATHIIN-3-CARBOXAMIDE UNIROYAL LTD. (CA) 1983-11-09 EP claimed
US-4247707-A CATALYTIC LIQUID-PHASE OXIDATION OF 2-METHYL-N-PHENYL-1,3-OXATHIOLANE-2-ACETAMIDE; THEN CATALYTIC THERMAL RING EXPANSION UNIROYAL CHEMICAL CO./UNIROYAL CHEMICAL CLE. (CA) 1981-01-27 US claimed
EP-0010843-A1 Method of making 5,6-dihydro-2-methyl-N-phenyl-1,4-oxathiin-3-carboxamide UNIROYAL LTD. (CA) 1980-05-14 EP claimed
WO-2026087965-A1 COMPOSITION COMPRISING EPOXY RESIN WITH CONSTRAINED AROMATIC RINGS AND PHOTOBASE 3M INNOVATIVE PROPERTIES COMPANY (US) 2026-04-30 WO disclosed
US-12479781-B2 Process for the preparation of ethylene glycol SHELL USA, INC. (US) 2025-11-25 US disclosed
US-12479856-B2 Pharmaceutical compounds for the treatment of complement mediated disorders ACHILLION PHARMACEUTICALS, INC. (US) 2025-11-25 US disclosed
WO-2025200154-A1 TWO-PART EPOXY COMPOSITION COMPRISING THIOL CURATIVE, AND CATALYST 3M INNOVATIVE PROPERTIES COMPANY (US) 2025-10-02 WO disclosed
US-4554010-A 5-Deoxy-3-O-arylmethyl or substituted arylmethyl-1,2-O-substituted-alkylidene-alpha-D-xylofuranose herbicide derivatives CHEVRON RESEARCH COMPANY (US) 1985-11-19 US disclosed
US-4515618-A PLANT GROWTH REGULATORS CHEVRON RESEARCH COMPANY (US) 1985-05-07 US disclosed
US-4429119-A PLANT GROWTH REGULATORS CHEVRON RESEARCH COMPANY (US) 1984-01-31 US disclosed
US-4247707-A CATALYTIC LIQUID-PHASE OXIDATION OF 2-METHYL-N-PHENYL-1,3-OXATHIOLANE-2-ACETAMIDE; THEN CATALYTIC THERMAL RING EXPANSION UNIROYAL CHEMICAL CO./UNIROYAL CHEMICAL CLE. (CA) 1981-01-27 US disclosed
US-4160116-A FROM THE CORRESPONDING OXIDE BY HYDRATION USING ORGANIC PHOSPHONIUM HALIDE CATALYST, CARBON DIOXIDE SHOWA DENKO K.K. (JP) 1979-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12479856-B2 Pharmaceutical compounds for the treatment of complement mediated disorders C5, CFH, C1QBP KIF11 3145/4885KCNN4 3362/4885CYP11B1 1778/4885
US-20150274728-A1 METHOD FOR PREPARING AN IMPORTANT INTERMEDIATE OF LINAGLIPTIN DPP4, DPP9, DPP3 KIF11 2763/4885KCNN4 2399/4885CYP11B1 3197/4885
US-12479781-B2 Process for the preparation of ethylene glycol GYS1, LIPG, LIPE KIF11 3352/4885KCNN4 4423/4885CYP11B1 426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.